Work Here?
About Fractyl Health
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Lexington, Kentucky
Founded
2010
Overview
Fractyl focuses on creating therapies for Type 2 Diabetes (T2D) and obesity, targeting the root causes of these metabolic diseases. Their main product, Rejuva, is a gene therapy platform aimed at improving the function of pancreatic islet cells, which are essential for blood sugar regulation. By enhancing these cells, Fractyl seeks to achieve long-term remission for patients with T2D and obesity. Currently, Rejuva is in preclinical development and has received a CE mark for commercial availability in Europe, although it is still awaiting full FDA approval. Unlike many competitors, Fractyl's approach centers on addressing the underlying mechanisms of these diseases rather than just managing symptoms. The company's goal is to transform the treatment landscape for T2D and obesity, ultimately preventing and eliminating these conditions.
Simplify's Take
What believers are saying
- Rejuva's CE mark approval aids European market expansion.
- Partnership with Forge Biologics boosts gene therapy production capabilities.
- Adrian Kimber's appointment strengthens commercialization strategies for Revita.
What critics are saying
- Competition from established firms may impact Fractyl's market share.
- FDA approval delays could hinder Rejuva's commercialization.
- High gene therapy development costs may strain financial resources.
What makes Fractyl Health unique
- Fractyl Health focuses on minimally invasive therapies for chronic diseases.
- The Rejuva platform targets root causes of Type 2 Diabetes and obesity.
- Fractyl's Revita DMR rejuvenates the duodenum lining to improve patient health.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$420.2M
Above
Industry Average
Funded Over
8 Rounds
Bessemer Venture Partners
General CatalystBenefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -2%2 year growth
↓ -2%Forge Biologics partners with Fractyl Health on AAV manufacturing for metabolic gene therapy.
Fractyl is also working on a gene therapy platform called Rejuva.
BURLINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the first quarter 2025 and provide business updates on Tuesday, May 13, 2025, at 4:30 p.m. ET.A live webcast of the conference call can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the BofA Securities 2025 Health Care Conference on Wednesday, May 14, 2025, at 5:00 p.m. PT (8:00 p.m. ET).A live webcast of the presentation can be accessed in the “Events” section of Fractyl Health’s website at https://ir.fractyl.com/
Conservest Capital Advisors Inc. makes new $132,000 investment in Fractyl Health, Inc. (NASDAQ:GUTS).
At DDG, Fractyl Health will present new clinical updates on its ongoing real-world registry study of Revita(R) in patients with T2D in Germany
There are no jobs for Fractyl Health right now.
Find jobs on Simplify and start your career today
About Fractyl Health
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Lexington, Kentucky
Founded
2010
There are no jobs for Fractyl Health right now.
Find jobs on Simplify and start your career today